REASSORTANT STRAIN OF INFLUENZA VIRUS B/60/WASHINGTON/2019/3676 (VICTORIA LINE) FOR THE PRODUCTION OF LIVE INFLUENZA INTRANASAL VACCINE FOR ADULTS AND CHILDREN Russian patent published in 2021 - IPC C12N7/00 A61K39/145 

FIELD: virology.

SUBSTANCE: invention relates to virology. The vaccine strain B/60/Washington/2019/3676 (Victoria line) is described - a reassortant obtained by crossing the "wild" virus B/Washington/02/2019 (Victoria line) with a cold-adapted temperature-sensitive virus B / USSR / 60/69 - a donor attenuation, harmless to humans. Strain B/60/Washington/2019/3676 (Victoria line) actively multiplies in developing chicken embryos at an optimum temperature of 32°С, is characterized by temperature sensitivity and cold adaptation and harmlessness to laboratory animals. The reassortant inherited genes encoding the hemagglutinin (HA) and neuraminidase (NA) virus surface antigens from the epidemic parental virus, and the remaining six genes encoding internal and non-structural proteins from the attenuation donor. Thus, the vaccine strain B/60/Washington/2019/3676 (Victoria line), in terms of the main biological properties studied in preclinical in vitro and in vivo experiments, meets the requirements for vaccine strains of the Pharmacopoeia Monograph (FSP: P N003224/01- 270313) on Ultravak®, live allantoic influenza vaccine for intranasal use for adults and children.

EFFECT: invention can be used in practical health care for the prevention of the incidence of influenza among adults and children using a live influenza intranasal vaccine from the influenza virus strain B/60/Washington/2019/3676 (Victoria line) in the case of spread in the human population of similar influenza viruses.

1 cl, 4 tbl